When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
 Benefits are available in the member's contract/certificate, and  Medical necessity criteria and guidelines are met.
Based on review of available data, the Company may consider nintedanib (Ofev ® ) ‡ or pirfenidone (Esbriet ® ) ‡ for the treatment of idiopathic pulmonary fibrosis (IPF) to be eligible for coverage.**
Patient Selection Criteria
Coverage eligibility for nintedanib (Ofev) or pirfenidone (Esbriet) will be considered when all of the following criteria are met:  Ofev and Esbriet are NOT used as combination therapy; AND  Patient has a confirmed diagnosis of IPF by: o Exclusion of other know causes of interstitial lung disease (e.g., domestic and occupational environmental exposures, connective tissue disease, drug toxicity); AND  The presence of usual interstitial pneumonia pattern on high-resolution computed tomography (HRCT) in patients not subjected to surgical lung biopsy; OR  A combination of HRCT and surgical lung biopsy pattern that is indicative of a diagnosis of IPF in patients subjected to surgical lung biopsy.
When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.
Based on review of available data, the Company considers the use of nintedanib (Ofev) or pirfenidone (Esbriet) when patient selection criteria are NOT met to be investigational.*
Background/Overview
There are currently only two drugs that are FDA approved for the treatment of IPF, Ofev and Esbriet. Ofev is a small molecule that inhibits multiple receptor tyrosine kinase and non-receptor tyrosine kinases. It is believed that Ofev mainly works by vascular endothelial growth factor (VEGFR) inhibition. Ofev is dosed at 150mg twice daily. There is also consideration for dose reductions as the drug is also supplied in a 100mg capsule dosage form. Esbriet's mechanism of action is unknown, however it does belong to the chemical class of pyridone drugs. Esbriet is dosed at 801mg (three 267mg capsules) three times a day. Dose modifications are also recommended for this drug. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a rare, chronic, fatal disease characterized by a progressive and irreversible loss of lung function (decline in forced vital capacity [FVC]). Idiopathic pulmonary fibrosis usually occurs in middle aged to elderly adults, and is more common in males. Survival rates are poor in patients with IPF.
FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
Both Esbriet and Ofev were approved in October of 2014 for the treatment of IPF. These two agents are the first drugs that are FDA approved for this indication.
Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
The clinical efficacy of Ofev was established in 3 pivotal trials (Studies 1, 2, and 3) . These were randomized, double-blind, placebo-controlled studies comparing treatment with Ofev 150 mg twice daily to placebo for 52 weeks. Studies 2 and 3 were identical in design. Study 1 was very similar in design. Patients were randomized in a 3:2 ratio (1:1 for Study 1) to either Ofev 150 mg or placebo twice daily for 52 weeks. Study 1 also included other treatment arms (50 mg daily, 50 mg twice daily, and 100 mg twice daily) that are not further discussed. The primary endpoint was the annual rate of decline in FVC. Time to first acute IPF exacerbation was a key secondary endpoint in Studies 2 and 3 and a secondary endpoint in Study 1. Change from baseline in FVC percent predicted and survival were additional secondary endpoints in all studies. A statistically significant reduction in the annual rate of decline of FVC (in mL) was demonstrated in patients receiving Ofev compared to patients receiving placebo based on the random coefficient regression model, adjusted for gender, height, and age. The rate of decline for Ofev in the 3 studies ranged from -60mL to -115mL vs. a rate of decline ranging from -191mL to -240mL in the placebo group. The treatment effect on FVC was consistent in all 3 studies. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
